Pfizer, Octapharma Partner
Octapharma and Pfizer form an agreement for the future marketing and commercialization of human prothrombin complex concentrate.
Octapharma AG, a Swiss manufacturer of human protein products, has entered into an agreement with Pfizer for the future marketing and commercialization of human prothrombin complex concentrate (PCC), an investigational agent currently under FDA review for the urgent reversal of Vitamin K antagonist therapy in adult patients who require surgery or invasive procedures. Under the agreement, Octapharma AG has exclusive rights to commercialize this product globally, with the exception of the US, where Pfizer will exclusively be responsible for marketing and commercialization.
The biologics license application for the product was submitted by Octapharma AG in April 2013 and is currently under FDA review. Octapharma AG’s PCC is approved for use in 75 countries outside the US under the brand name Octaplex and was first approved for use in Germany in 2003 (it is branded as Ocplex in Sweden and Pronativ in Australia).
Source: Octapharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
